Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm

Learn more about:
Related Clinical Trial
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery Safety and Clinical Effectiveness of Pipeline™ Shield Devices for Intracranial Aneurysms Intraoperative Fluorescence With Augmented Reality Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH) Amnesia After Surgery for Anterior Communicating Aneurysm: High Resolution Magnetic Resonance (MR) Imaging Findings Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage The RISE Trial: A Randomized Trial on Intra-Saccular Endobridge Devices Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy Esmolol Infusion in Patients Undergoing Craniotomy Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing. Registry for Study of Coils in Intracranial Aneurysms EEG Monitoring to Assess Emergence From Neuroanesthesia DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial Hydrogel Endovascular Aneurysm Treatment Trial Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment Doppler Flow Wires in Cerebral Angiography Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms Impact of Acute Cerebral Diseases on the Autonomous Nervous System: Progression and Correlation to Therapy and Outcome New Findings About Somatosensory Evoked Potentials (SEP) During Surgery for Cerebral Aneurysms Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity Use of Classic LMA During Endovascular Therapy HydroCoil Cerebral Aneurysm Treatment Trial Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm Goal-directed Therapy in Endovascular Coiling of Cerebral Aneurysm Patients Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2 Decision Aids in Cerebral Aneurysm Treatment Framing Eighteen Coils in Cerebral Aneurysms Trial Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 1

Brief Title

Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm

Official Title

Ticagrelor Versus Clopidogrel for Platelet Inhibition in Patients Undergoing Neurovascular Stenting for Intracranial Aneurysm

Brief Summary

      Part of interventional neuroradiology procedures for the treatment of selected cerebral
      aneurysms are now based on stenting. To reduce thromboembolic events, dual antiplatelet
      therapy (APT) combining aspirin and clopidogrel is proposed with close monitoring, since 1/3
      of the patients are low responders due to variation of the biological response to clopidogrel
      . Ticagrelor is used by few teams but has never been evaluated in a randomized controlled
      trial. It could be an option for APT due to more reproducible response with less
      interindividual variability and reduced monitoring. The aim of this study is to demonstrate
      the interest of ticagrelor for the dual APT for platelet inhibition, in patients undergoing
      neurovascular stenting for cerebral aneurysm.

Study Phase

Phase 3

Study Type


Primary Outcome

proportion of patients requiring at least one change of drug or dose adjustment to achieve platlet functional inhibition


Cerebral Aneurysm



Study Arms / Comparison Groups

Description:  clopidogrel: 75mg and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

December 2015

Completion Date

September 16, 2021

Primary Completion Date

June 16, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  unruptured cerebral aneurysm

          -  elective endovascular treatment

          -  stenting required

          -  dual antiplatelet therapy required

        Exclusion Criteria:





18 Years - N/A

Accepts Healthy Volunteers



, (33)1 48 03 6431, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Study Sponsor

, , 

Verification Date

June 2020